Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Relay Therapeutics (RLAY) over the last 5 years, with Sep 2025 value amounting to $17,000.

  • Relay Therapeutics' Cash from Financing Activities fell 99.99% to $17,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $221.2 million, marking a year-over-year decrease of 24.04%. This contributed to the annual value of $270.2 million for FY2024, which is 677.35% up from last year.
  • As of Q3 2025, Relay Therapeutics' Cash from Financing Activities stood at $17,000, which was down 97.88% from $800,000 recorded in Q4 2024.
  • In the past 5 years, Relay Therapeutics' Cash from Financing Activities registered a high of $384.0 million during Q4 2021, and its lowest value of $17,000 during Q3 2025.
  • In the last 3 years, Relay Therapeutics' Cash from Financing Activities had a median value of $2.1 million in 2023 and averaged $33.9 million.
  • As far as peak fluctuations go, Relay Therapeutics' Cash from Financing Activities skyrocketed by 685,635.71% in 2021, and later plummeted by 99.99% in 2025.
  • Over the past 5 years, Relay Therapeutics' Cash from Financing Activities (Quarterly) stood at $384.0 million in 2021, then slumped by 99.70% to $1.2 million in 2022, then surged by 1,779.76% to $21.9 million in 2023, then plummeted by 96.35% to $800,000 in 2024, then plummeted by 99.99% to $17,000 in 2025.
  • Its Cash from Financing Activities was $17,000 in Q3 2025, compared to $800,000 in Q4 2024 and $218.9 million in Q3 2024.